Status:
COMPLETED
BeneFIX Drug Use Results Survey [All-Case Surveillance]
Lead Sponsor:
Pfizer
Conditions:
Hemophilia B
Eligibility:
All Genders
Brief Summary
The survey is intended to investigate the following matters, etc. under the actual use status after marketing in all patients who are administered this drug for a certain period of time after the laun...
Detailed Description
Patients with hemophilia B (congenital blood coagulation factor IX deficiency) who are administered this drug. Patients with hemophilia B are either patients for whom treatment was already started wi...
Eligibility Criteria
Inclusion
- All patients with hemophilia B scheduled to receive treatment with BeneFIX will be eligible for the surveillance.
- No patient will be excluded because of prior inhibitor history; however, complete patient history and demographics will be collected.
Exclusion
- Patients not administered BeneFIX.
Key Trial Info
Start Date :
October 29 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 27 2017
Estimated Enrollment :
314 Patients enrolled
Trial Details
Trial ID
NCT01154231
Start Date
October 29 2009
End Date
February 27 2017
Last Update
July 16 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tokyo Medical University Hospital
Shinjuku-ku, Tokyo, Japan